3篇
您的检索式：作者名="Andrea Coinu"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis显示文摘 | Fausto Petrelli Andrea Coinu Karen Borgonovo Mary Cabiddu Mara Ghilardi Veronica Lonati Sandro Barni | 2014 | Breast Cancer Research and Treatment2014，，2： | 1 |
| 2 | Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials显示文摘BACKGROUND:Progression-free survival(PFS)has not been extensively investigated as a surrogate for survival in the firstline treatments of pancreatic cancer.The aim of this review was to evaluate PFS as a potential surrogate endpoint for overall survival(OS)in advanced pancreatic cancer in trials comparing poly-chemotherapy to gemcitabine alone. | Fausto Petrelli Andrea Coinu Karen Borgonovo Mary Cabiddu Sandro Barni | 2015 | Hepatobiliary & Pancreatic Diseases International2015，14，2： | 1 |
| 3 | Which strategy after first-line therapy in advanced colorectal cancer?显示文摘Second-line therapy for advanced colorectal cancer is an integral part of the treatment strategy that needs to be set from the beginning for each patient, bearing in mind the expected toxicities of chosen treatments, the patient's clinical condition, comorbidities, preferences, the aims of the treatment and the molecular status. Furthermore, the distinction between lines of therapy is no longer absolute. The perspective of 'continuum of care' includes switching chemotherapy prior to disease progression, maintenance therapy, drug 'holidays' if needed, surgical resection of metastases in selected patients, and seems to allow a tailored treatment, in which patients are more likely to benefit from exposure to all active agents, which is known to correlate with overall survival. The scenario of second-line treatment has changed dramatically over the years and could currently benefit from several options including chemotherapy with a single agent or in combination and the addition of molecular-targeted agents developed in the last decade, such as epidermal growth factor receptor antibodies(cetuximab, panitumumab) and vascular endothelial growth factor-targeting agents(bevacizumab, aflibercept), with the possibility of bevacizumab use even beyond first progression. The purpose of this review is to summarize the most important scientific data supporting the use of chemotherapy and the new biologic agents in the second-line setting in advanced colorectal cancer. | Coinu Andrea Petrelli Fausto Borgonovo Karen Francesca Cabiddu Mary Ghilardi Mara Lonati Veronica Barni Sandro | 2014 | World Journal of Gastroenterology2014，20，27： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员